My ePortfolio Register   

BRIM8: Vemurafenib in high risk melanoma patients

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 11.09.17
Views: 731

Dr Karl Lewis - University of Colorado Denver, Colorado, USA

Dr Lewis talks with ecancer at the ESMO 2017 Congress in Madrid about the BRIM8 study of adjuvant vemurafenib in patients with completely resected, BRAFV600 melanoma at high risk for recurrence. 

Dr Lewis goes on to discuss the results stating that median disease-free survival was greater, though not statistically significant, with adjuvant vemurafenib vs placebo. 

For more information watch the press conference here.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence